Advertisement
UK markets closed
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • CRUDE OIL

    82.96
    -0.40 (-0.48%)
     
  • GOLD FUTURES

    2,335.30
    -6.80 (-0.29%)
     
  • DOW

    38,503.11
    -0.58 (-0.00%)
     
  • Bitcoin GBP

    51,612.57
    -1,850.20 (-3.46%)
     
  • CMC Crypto 200

    1,386.88
    -37.22 (-2.61%)
     
  • NASDAQ Composite

    15,724.24
    +27.60 (+0.18%)
     
  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     

Can The Uptrend Continue for BioLife Solutions (BLFS)?

Tilly's (TLYS) closed the most recent trading day at $16.18, moving -0.98% from the previous trading session.

BioLife Solutions, Inc. BLFS has been on the move lately as the stock has risen by 44.6% in the past four weeks, and it is currently trading well above its 20-Day SMA. This is a pretty solid move higher, but the question that has to be on investors’ minds right now is; can this trend continue?

While there can be no telling for sure, it is certainly encouraging that earnings estimates have risen in the past few weeks on the company, suggesting that sentiment on BLFS is moving in the right direction. In fact, the stock currently has a Zacks Rank #2 (Buy), suggesting that the recent run could certainly continue for this in-focus company. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

ADVERTISEMENT

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
To read this article on Zacks.com click here.